Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
Ben
B
Warner
Adam W
AW
Harris
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male
D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized